<?xml version="1.0" encoding="UTF-8"?>
<p>Still now there is no specific antiviral drug to treat nCOVID-19, but some of the investigational drugs were found to be useful. Various drugs are being analyzed 
 <italic>in vitro</italic> studies or clinical trials. Although ribavirin is a potent antiviral drug, its clinical effects are not clear and its side effects ought to be carefully considered. On the other hand, chloroquine has been studied in 15 interventional studies. Furthermore, in the Chinese Clinical Trial Registry, the derivatives of chloroquine were prospectively registered; and more studies are required to evaluate their antiviral effects and to estimate the recommended dose in nCOVID-19 patients (Zhang et al., 
 <xref rid="B214" ref-type="bibr">2020a</xref>). Along with antiviral drugs, glucocorticoids ought to be utilized carefully and in a timely manner in nCOVID-19 patients. In addition to this, extracorporeal support need to be considered under strict contraindications and indications, otherwise, there will be numerous additional complications and also a waste of resources (Zhang et al., 
 <xref rid="B214" ref-type="bibr">2020a</xref>).
</p>
